Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

NCT ID: NCT05667649

Last Updated: 2025-04-04

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-14
• Study Completion Date: 2026-08-31

Brief Summary

This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.

Detailed Description

This is a Phase 1, Open-Label Safety Study of Escalating Doses of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs) in Participants with Mild to Moderate Alzheimer's Disease (AD) whose Treatment is not Addressed Adequately by Available Therapy (i.e., an unmet medical need). The investigational product, which is referred to as RB-ADSC, consists of stem cells obtained from the participant's own adipose tissue by lipoaspirate. After collection, the stem cells are cultured and expanded outside the body, and then reintroduced into the same patient. A soft plastic reservoir (Ommaya reservoir) is implanted under the scalp, communicating with the brain cavities (ventricles). This study will primarily evaluate the safety of RB-ADSC injected in the Ommaya reservoir in a 3 + 3 dose escalation study. The planned enrollment will be 9 participants, 3 participants per escalation Cohort.

The primary objectives will evaluate adverse events, serious adverse events, and dose limiting toxicities to determine a recommended phase 2 clinical trial dose. Secondary objectives will evaluate preliminary efficacy measured by clinical assessments, volumetric MRI (Neuro Quant®), CSF biomarkers (Phospho-Tau, Total Tau, AB-42), and diagnostic imaging comparison (Amyloid PET). Each participant will be followed for 12 months after treatment.

Conditions

Alzheimer Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RB-ADSC low dose

Participants will receive one dose of 2x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir

Group Type: EXPERIMENTAL

RB-ADSC

Intervention Type: BIOLOGICAL

Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)

RB-ADSC medium dose

Participants will receive one dose of 5x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir

Group Type: EXPERIMENTAL

RB-ADSC

Intervention Type: BIOLOGICAL

Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)

RB-ADSC high dose

Participants will receive one dose of 10x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir

Group Type: EXPERIMENTAL

RB-ADSC

Intervention Type: BIOLOGICAL

Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)

Interventions

RB-ADSC

Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• ≥45 and ≤80 years of age
• Mild to moderate AD diagnosis
• Adequate cognitive function
• Non-remarkable clinical laboratory
• Ability to voluntarily provide written informed consent
• No tumors or other disease responsible for dementia
• Well-controlled comorbidities, on stable medications for 3 months
• The participant is otherwise in good general health
• The participant must have a relative/caregiver
• Participant must be able to donate adequate amount of lipoaspirate to establish the final product

Exclusion Criteria

• Taking other medications for AD, except that donepezil memantine, AChEIs including patches, Vitamin E, fish oil, and/or gingko biloba are allowed if doses have been stable for at least 3 months prior to the Screening visit
• Stem cell implantation of any type within 3 months
• Existing ventriculoperitoneal shunts
• Neurological disorders except AD
• Psychiatric disorders including schizophrenia, bipolar/unipolar depressive disorder, delirium
• Drug or alcohol abuse or dependence within the past 5 years
• Participants with a history of cancer in the past 5 years

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Regeneration Biomedical, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Robert Lynn

Role: primary

robert@regenerationbiomedical.com

877-240-1660

References

Duma C, Kopyov O, Kopyov A, Berman M, Lander E, Elam M, Arata M, Weiland D, Cannell R, Caraway C, Berman S, Scord K, Stemler L, Chung K, Khoudari S, McRory R, Duma C, Farmer S, Bravo A, Yassa C, Sanathara A, Singh E, Rapaport B. Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients. Mol Biol Rep. 2019 Oct;46(5):5257-5272. doi: 10.1007/s11033-019-04983-5. Epub 2019 Jul 20.

Reference Type: BACKGROUND

PMID: 31327120 (View on PubMed)

Other Identifiers

RB-ADSC-02

Identifier Type: -

Identifier Source: org_study_id